Autologous Anti-CLL-1 CAR T-cells ARD103

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that are genetically modified and transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) C-type-lectin-like molecule-1 (CLL-1; CLL1; C-type lectin domain family 12 member A; CLEC12A) and linked to the co-stimulatory signaling domains CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CLL-1 CAR T-cells ARD103 specifically target and bind to CLL-1-expressing tumor cells. This induces selective toxicity in CLL-1-expressing tumor cells. CLL-1, a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed in acute myeloid leukemia (AML) blast cells and leukemic stem cells (LSCs) while being absent on normal hematopoietic stem cells (HSCs). It plays an important role in disease progression and relapse in myeloid malignancies.

**Synonyms:** - ARD 103 - ARD-103 - ARD103 - Autologous Anti-CLL-1 CAR T Cells ARD103 - Autologous Anti-CLL1 CAR-T Cells ARD103